Confocal microlaparoscope for imaging the fallopian tube

Abstract

Abstract. Recent evidence suggests that ovarian cancer can originate in the fallopian tube. Unlike many other cancers, poor access to the ovary and fallopian tubes has limited the ability to study the progression of this deadly disease and to diagnosis it during the early stage when it is most amenable to therapy. A rigid confocal microlaparoscope system designed to image the epithelial surface of the ovary in vivo was previously reported. A new confocal microlaparoscope with an articulating distal tip has been developed to enable in vivo access to human fallopian tubes. The new microlaparoscope is compatible with 5-mm trocars and includes a 2.2-mmdiameter articulating distal tip consisting of a bare fiber bundle and an automated dye delivery system for fluorescence confocal imaging. This small articulating device should enable the confocal microlaparoscope to image early stage ovarian cancer arising inside the fallopian tube. Ex vivo images of animal tissue and human fallopian tube using the new articulating device are presented along with in vivo imaging results using the rigid confocal microlaparoscope system. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI.

Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer Risk

“…Using prospectively collected biospecimens from predefined cohorts, we leveraged "bedside-tobench" reverse translational research in hypothesis-driven, investigator-initiated trials (IIT). Central to our research has been the pursuit of early detection and prevention for women who are at HR for developing ovarian cancer [5][6][7][8]. Consequently, we initiated a phase 2 study (flutamide IIT NCT00699907) to assess the role of the anti-androgen flutamide in modulating gene expression and influencing potential biomarkers in HR women.…”

Highly Specific, Fluorescent Cannabinoid Type 2 Receptor Probes Enable Applications in Microscopy, Flow Cytometry and FRET-based Binding Assays

“…[21][22][23] Several fluorescent ligands targeting CB2R have been reported. [24][25][26][27][28][29][30][31][32][33][34] In our collective experience, however, the published probes perform less than optimally, as judged by at least one of the following criteria: CB2R affinity and specificity, selectivity over CB1R, photophysical properties, and applicability across species, distinct techniques, and cell types. Furthermore, bifunctional probes that require additional manipulations prior to imaging are not compatible with live cell imaging.…”

Multispectral fluorescence imaging of human ovarian and fallopian tube tissue for early-stage cancer detection

“…Optical techniques can be miniaturized for endoscopy, are robust, and are relatively inexpensive. Ovarian cancer has been imaged by several microscopic optical modalities in the past, including optical coherence tomography (OCT), [10][11][12][13][14] confocal microscopy, [15][16][17][18] multiphoton microscopy (MPM), 19,20 photoacoustic imaging (PAI), 13,[21][22][23] and fluorescence spectroscopy/imaging. [24][25][26][27] OCT captures high-resolution depth images of tissue microstructure and has demonstrated ability to distinguish normal tissue from ovarian cancer in vivo in animal models 28 and laparoscopically in vivo in human patients.…”

“…10 Fluorescence confocal imaging has been integrated into a microlaparoscope and has the ability to detect cancerous tissue in vivo. [16][17][18] High-quality images of nuclear size and shape are obtained by the use of contrast agents, which have not yet been approved by the U.S. Food and Drug Administration (FDA) for in vivo use. MPM, including second-harmonic generation and multiphoton excited fluorescence, can image cell and connective tissue structure and metabolic tissue properties.…”